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Abstract 
Objective: To provide an in-depth understanding of patients' views about the impact 
of transcatheter aortic valve implantation on self-reported quality of life. Background: 
Transcatheter aortic valve implantation is considered to be the gold standard of care 
for inoperable patients diagnosed with severe symptomatic aortic stenosis. Mid- to 
long-term clinical outcomes are favourable and questionnaire data indicates 
improvements in quality of life but an in-depth understanding of how quality of life is 
altered by the intervention is missing. Methods: A mixed methods study design with 
a total of 89 in-depth qualitative interviews conducted with participants (39% male; 
mean age 81.7 years), 1 and 3 months post TAVI, recruited from a regional centre in 
England. Data were triangulated with questionnaire data (SF-36 and EQ5D-VAS) 
collected, pre, 1 and 3 months post implantation. Results: Participants' accounts 
were characterised by four key themes; shortened life, extended life, limited life and 
changed life. Quality of life was changed through two mechanisms. Most participants 
reported a reduced symptom burden and all explained that their life expectancy was 
improved. Questionnaire data supported interview data with gradual improvements in 
mean EQ-5D scores and SF-36 physical and mental domain scores at 1 and 3 
months compared to baseline. Conclusion: Findings suggest that TAVI was of 
variable benefit, producing considerable improvements in either mental or physical 
health in many participants, while a smaller proportion continued to deteriorate. 
 
Introduction  
The ageing of the population means that by 2050 one in five people will be over 60 
years of age.1 Acquired aortic stenosis (AS) is typically a disease of ageing which 
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affects up to 12% of people over 75 years of age.2 If we consider the demographic 
picture of China as an example, we know that by 2050 about 100 million people  will 
live to be over 80 years old.3 This would equate with up to 12 million people living 
with AS which could make a substantial impact on health service provision.  
 
In acquired AS, the narrowed aortic valve causes systolic and diastolic dysfunction 
with unpleasant symptoms such as dizziness, fainting and chest pain leading to 
reduced quality (QoL) and quantity of life.4 Global policy emphasises the importance 
of 'healthy ageing'; a process in which optimal physical and mental capacity is 
retained.1 Therefore interventions that can reduce the AS symptom burden offer an 
important treatment for what is a growing global population of older adults.    
 
Transcatheter aortic valve implantation (TAVI), first described in 19925  and further 
developed in 2002,6 offers an alternative and revolutionary treatment option to 
surgical valve replacement. TAVI involves the placement of a prosthetic valve inside 
the narrowed aortic valve using a balloon catheter. Trial data comparing SAVR and 
TAVI shows favourable mid-to-long term outcomes for this innovative treatment.7-8  
Data from several large registry studies reported 30-day, 1-year, and 5-year mortality 
rates after TAVI as around 6%, 24% and 50% respectively.9   
 
Careful assessment of suitable TAVI candidates is required in view of the mortality 
risk and the potential of TAVI heart valve degeneration. The evaluation of QoL is 
recognised as an important consideration in identifying patients who might benefit 
from TAVI.10  Quantitative data presented in systematic reviews report improvements 
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in self-reported QoL after TAVI.11,12 Moreover QoL measured pre-TAVI is a predictor 
of QoL over a 2 year recovery period.13  
There are a handful of published qualitative studies that describe the patient 
experience leading up to TAVI treatment but very little information about the recovery 
experience. Being on the TAVI waiting list is a stressful period as physical function 
continues to decline and patients reported a sense of 'living on the edge'.14 One 
systematic review highlighted a lack of research about AS patients’ values, 
preferences for different treatment options.15  To make a decision about treatment 
options it is important that the patients has information about what the recovery 
pattern might involve and what they might expect. We were unable to identify other 
qualitative studies that explained how TAVI impacted on self-reported QoL. 
Understanding the patients’ perspective is important as the views of health 
professionals, patients and their families about QoL do not always match,16  but 
health professionals’ views  typically determine patient access to treatment.17   
The aim of the study was to provide an in-depth understanding of patients’ views 
about how TAVI impacts upon QoL during early recovery (T1 baseline, T2 1 month 
post TAVI and T3 3 months post TAVI) through a series of interviews, complemented 
by quantitative data collected using validated QoL measures.  
Methods  
We explored QoL in participants treated with TAVI using a mixed methods design. 
This study design was chosen to develop a comprehensive and robust knowledge 
base supported by the triangulation of findings. The qualitative and quantitative 
studies ran concurrently in a convergent parallel study design20. The qualitative study 
took precedence (QUAL quan), drawing upon the principles of ethnographic 
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research which emphasise the exploration of phenomena. Using this approach we 
conducted a series of interviews which supported prolonged participant engagement 
and enabled us to explore participants views of how TAVI influenced their QoL.21 
The quantitative study identified trends in QoL scores to inform the qualitative 
analysis.  
QoL and health-related QoL are terms that are often used interchangeably, but the 
former is a broader concept than the latter. There are several published QoL models, 
but no consensus about the most appropriate.18 We chose the WHO ICF19 
framework to provide us with a theoretical context because it is a biopsychosocial 
model that can be used across countries; is appropriate for outcome evaluation, and 
is recognised as a standard for health professionals, policy makers and the public.18  
Sample and setting: All participants scheduled for TAVI at a single regional centre 
in the North of England servicing a population of over 2 million were invited to 
participate. The sample comprised English speaking participants with a Mini Mental 
State Examination22 (MMSE) score of ≤17 and the capacity to provide informed 
consent.  A maximum variation approach to sampling was adopted in which 
participants are purposefully selected to capture a variety of participant experiences 
by gender and age group.  
Procedure: Eligible patients were identified by clinical staff not directly involved in 
the study. After providing informed consent participants completed a series of up to 
two in-depth, face-to-face, semi-structured qualitative interviews conducted in their 
home setting. Data collection points (1 and 3 months post TAVI) were chosen 
because cardiac patients and their carers find the early post-discharge period of 
recovery challenging.23  All participants were asked open ended questions such as 
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'Tell us about your experience of the TAVI procedure',  'Have  any aspect of your life 
changed because of TAVI treatment?', 'Do you think having TAVI has influenced 
your quality of life?', 'If yes then how has this happened and what has changed?'. To 
support the quality of the data collection, one experienced researcher, trained in 
qualitative methods, conducted all interviews supplemented by field notes, until data 
saturation was confirmed.  
Data analysis  
Qualitative interviews 
Framework analysis was chosen to explore emerging concepts within the interview 
data on a case-by-case basis.24 An initial coding framework was independently 
developed by three researchers, following the coding of the first five interview 
transcripts. Themes that are presented represent unifying concepts or statements 
about the impact of TAVI upon QoL during a 3 month recovery period. Data 
interpretation was authenticated through a series of audiorecorded team meetings in 
which decisions about the analytical process were discussed, disconfirming cases 
reviewed and potential sources of researcher bias considered. The researchers 
resolved any diagreement in the analytical process by revisiting raw data and 
reviewing the fit of interpretations. This process of reflexivity with a key audit trail of 
decision making, along with the triangulation of data and investigators added to the 
trustworthiness of findings.25 NVivo (version 9) was used to organise, manage and 
retrieve data.26 
Quantitative measurement 
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Demographic data were collected on all respondents (age, gender and ethnicity), 
and health-related QoL as measured by the SF12 instrument (Version 2) (PCS and 
MCS scales) and the EQ-5D VAS completed. Data were cleaned and entered into 
SPSS (version 22).  
 
Measures 
Quality of Life: Physical and Mental Components 
QoL was measured using the Short Form-12 which is a generic measure that 
evaluates 8 health-related concepts, with scores being combined into mental and 
physical component summary scales (Physical Component Score-12 [PCS] and 
Mental Component Score-12 [MCS]). The general population have a mean score of 
50 on these measures, with higher scores representing better health.27 A general 
population of a comparable age range to this study reports a mean scores of 38.7 
and 50.1 on the PCS and MCS scales respectively27.  
Quality of Life: Perceived Health Status 
The visual analogue scale (VAS) of the EQ-5D28 (EuroQol-5 dimensions) was used 
to measure perceived health status (100 best imaginable health and 0 worst 
imaginable health) giving utility scores. A general population of a comparable age 
range to this study has  a mean score of 79.0 on this measure28.  
 
The sample was summarised descriptively. Mean and quartile scores (25th 
percentile, median, and 75th percentile scores) were obtained for each measure at 
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each time point. Values obtained from the study sample were compared against 
corresponding normative values applicable to a population of similar age range. The 
number and valid percentage of patients whose scores on each of the three 
measures matched corresponding age-adjusted population normative scores was 
obtained for each of time points T1, T2 and T3. For each measure at each time 
point, the significance of the change from the corresponding population normative 
scores was also derived. The number and valid percentage of patients who improved 
between each time point on all outcome measures was also determined. Repeated 
measures analyses of variance (ANOVAs) were conducted on each measure to 
assess the significance of the variation in scores on each measure with respect to 
the time factor. The magnitude of any change observed was quantified using the 
partial-2 statistic, with Bonferroni-corrected pairwise comparison tests conducted as 
post hoc procedures. 
3. Results 
The final sample composed 53 participants on the waiting list for TAVI. All 
participants were of Caucasian ethnicity and Table 1 shows sample characteristics. 
At T1 one patient had died, five had withdrawn and one could not be contacted but 
participated in later interview.  By three months, a further three patients had 
withdrawn from the study (see Table 2 for data collection points and recruitment).  
Insert Tables 1 and 2 about here please 
3.1 Interviews 
Participants’ accounts were characterised by four key themes (shown in Figure 1 
with accompanying categories and participants quotes). In summary TAVI impacted 
10 
 
on QOL in two ways; most participants reported a reduced symptom burden and all 
explained that their life expectancy was improved. Some participants explained that 
TAVI had given them hope as they had access to a treatment that could improve 
their health and that before there had been no other treatment options.     
 
Theme 1: Shortened Life 
1.1 Facing mortality 
A key concern for participants, as their AS progressed, was of impending death and 
the impact of this on their family and significant others. Some participants expressed 
fear of dying alone or concern about the impact of their death on a spouse. Other 
participants felt that they had lived their life and that there was little point worrying 
about events that could not be controlled. Those with extreme breathlessness felt 
that death might be preferable to their current life. Participants reported feeling 
scared, lonely and short-tempered as they waited for TAVI. An important part of the 
pre-TAVI consultation involved candid doctor-patient discussion about the risks, 
benefits and potential outcomes of TAVI, as well as the likely prognosis should no 
treatment be given. These discussions acted as a catalyst for reflection about the 
reality of mortality. Participants were typically in their eighth or ninth decade of life, 
and many had experienced mortality of family members or friends leading to 
changes in their personal relationships and social networks. Living with a life limiting 
condition often increased the emotional closeness between remaining family 
members.  
1.2 Deciding to have TAVI 
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The pre-TAVI consultation was an important part of the overall decision making 
about agreeing to TAVI. Participants' responses to the consultation varied. Some 
participants appreciated the candid and honest approach. Others found the 
information more distressing, and felt that there was more of an emphasis upon risks 
than benefits. This led to a re-evaluation of their current QoL which was an important 
influence upon the decision to go ahead with TAVI. All participants recognised that 
their life expectancy was shortened by their heart condition. For many TAVI offered a 
source of hope as they had access to a treatment option that could improve their life 
where they thought there had been none.   
Theme 2: Limited Life  
Participants health was severely affected by AS and other co-morbidities. The 
burden of symptoms limited their opportunity to live what was described as a 'full life' 
and day-to-day life for many was a 'struggle'.  
2.1 Symptom burden 
Before the procedure, the majority of participants reported moderate to severe 
breathlessness which led to physical restrictions which had a negative impact upon 
day-to-day life. The severity of breathlessness had a corresponding effect on energy 
levels and fatigue. Shortness of breath, dizziness, fainting and falls were common 
complaints, as were fatigue, pain, sleep disturbance, loss of memory, concentration 
and appetite. The degree of breathlessness was extreme for some participants who 
reported being frightened: (Female subject 14, 87 years, NYHA III). One participant 
was so breathless that she had to sleep in a chair, was unable to talk on the phone 
to her family and fearful to go anywhere alone. The increased level of dependence 
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on others to manage daily activities of living led some participants to report feeling 
worthless and burdensome.   
2.2 Functional and social restrictions  
Many aspects of participants’ lives were restricted by the symptom burden and 
associated physical limitations with leisure/social activities being the most affected. 
Participants often described feeling that they had lost their independence.  Many felt 
unable to leave their homes which led to functional and social restrictions. Being 
confined to home reduced social contact, leading to feelings of loneliness, isolation, 
boredom, loss of control and depressive symptoms. Many participants described 
feeling a loss of pleasure in life and a lack of motivation. Others  described 
restrictions on driving and taking holidays and the inability to participate in the day-
to-day activities of normal life; such as attending to hygiene needs, housework, meal 
preparation, gardening, and caring for other family members such as grandchildren. 
These activities were either no longer possible, or took much longer than before, 
which was a source of frustration and misery. Participants’ accounts clearly 
demonstrated the connection between physical functioning and psychological well-
being; as physical limitations increased, life became more restricted and 
psychological well-being declined.  
Theme 3: Extended Life 
TAVI was seen as an intervention that could treat a life-threatening heart condition 
and was preferable to SAVR.   
3.1 Survival 
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All participants were aware of their life limiting condition and the potential risks of 
having TAVI. Participants described their relief at having survived the TAVI 
procedure and gratitude about having access to this intervention. In addition, 
participants who had a successful TAVI procedure reported their perception of  
having a longer life span.  
Theme 4: Changed Life 
The reduced symptom burden and the prospect of a longer life was described as 'life 
changing' for many participants. The availability of a procedure that could offer the 
potential of a better life, particularly at their advanced age, was very much 
appreciated. After recovery there was a change evident for many participants in the 
nature of relationships with 'significant others'. Participants became more focused 
upon these connections and wanted a change in which they could be 'of use' to 
others, rather than simply a burden or source of concern.  
4.1 Symptomatic relief  
The mechanism through which TAVI made an impact on QoL was, for most 
participants, through a reduction in the burden of physical symptoms which were 
experienced daily. Many participants reported an improvement in their breathing as 
the best thing about TAVI. The magnitude and pace of improvement varied. Some 
participants experienced an immediate life changing and transformational 
improvement in their physical health, whilst others experienced a slower 
improvement.   
The scale of improvement was mediated by the existence of other health conditions. 
For example, several participants had hoped for a greater improvement in their 
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symptom burden, but other health conditions such as Chronic Obstructive Pulmonary 
Disease (COPD), or morbid obesity, appeared to counteract improvements after 
TAVI as the symptoms associated with these non-cardiac conditions were not 
relieved.  Living with several comorbidities meant that it was sometimes challenging 
for participants to evaluate the impact of TAVI upon their own symptom burden and 
QoL. Participants explained that it was difficult to understand which physical 
symptoms could be attributed to which health condition. The reduction in symptom 
burden changed some participants’ views about the desired length of their life which 
emphasises the significant impact of symptoms on psychological well-being and 
QoL. Others experienced a less dramatic change in their symptom burden but still 
reported some improvement. Many of the participants reported experiencing less 
fatigue after TAVI. Other reported that they were less short of breath and therefore 
able to go about their daily activities at a faster pace, which was a positive change. 
The improvement in their health influenced their mood, with participants and their 
family explaining that they were less short-tempered. No participants openly 
expressed regret about their decision to have TAVI, but one participant provided a 
contrasting view characterised by ambivalence; they acknowledged that the 
intervention had extended their life but their ongoing symptom burden had not 
changed to the extent that they had hoped.  
For those who did not experience the expected relief of physical symptoms the 
mechanism of improvement following TAVI was slightly different. For some TAVI 
functioned as a 'bridge' to other health interventions which had previously been 
unavailable due to poor health. One example was access to elective surgical 
procedures, such as a hip replacement, which if successful, would potentially further 
improve QoL. For others it was the notion that everything possible had been done to 
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try and improve their health. Another participant mentioned that the potential health 
improvement following TAVI would enable them to continue their role as a carer for 
their spouse.   
TAVI when successful, often enabled recipients to regain a level of functional 
capacity they had enjoyed at a younger age.  Several participants experienced what 
they described as the ‘turning back of time’ or a 'new lease of life'.     
4.2 Feeling safe  
Many participants described how TAVI offered them a feeling of ‘being safe’, ‘more 
confident’ with ‘peace of mind’. The immediate threat of death was removed and 
their heart was 'repaired' meaning that they could participate more fully in day-to-day 
activities. The significant reduction in symptoms that most participants experienced 
signalled a tangible improvement in their heart function which contributed to feelings 
of security. Even for those who did not experience a significant change in their 
symptoms there was a perception that everything had been done to try and improve 
their health. The increase in the level of confidence regarding their physical health 
enabled participants to return to some of the activities that had been dropped such 
as taking holidays. This enabled a fuller life and greater participation and 
engagement in social activities. 
 
3.2 Self-Reported Quality of Life SF-12, EQ5-VAS 
Tables 3 and 4 show the mean, standard deviation, quartiles scores for the PCS and 
MCS subscales of the SF12 scale and the EQ-5D VAS instruments; and range 
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scores for the SF12 subscales only. Corresponding population norms are also 
presented for comparison. 
Insert Tables 3, 4 about here please 
At T1 (baseline), population normative values were already exceeded in the mean 
SF-12 PCS scale by 6 out of 45 patients (13.3%); in the SF-12 MCS scale by 16 out 
of 45 patients (35.6%); and in the EQ5D-VAS scale by 8 out of 45 patients (17.8%). 
At T2 (1 month post-TAVI), these corresponding proportions had risen to 20 out of 
40 patients (50.0%) in the SF-12 PCS scale; to 21 out of 40 patients (52.5%) in the 
SF-12 MCS scale; and to 15 out of 40 patients (37.6%) in the EQ5D-VAS scale. At 
T3 (3 months post-TAVI), these corresponding proportions had stabilised to 20 out of 
39 patients (51.3%) in the SF-12 PCS scale; to 17 out of 39 patients (43.6%) in the 
SF-12 MCS scale; and to 15 out of 40 patients (37.6%) in the EQ5D-VAS scale. 
Single-sample t-tests show evidence that mean SF-12 PCS, SF-12 MCS and EQ5D-
VAS scores were significantly lower than corresponding population normative values 
at T1 (baseline) (p<0.001 for PCS; p=0.001 for MCS; p<0.001 for EQ5D-VAS). At T2 
(1 month post-TAVI), sample scores on the SF-12 PCS and SF-12 MCS scales had 
recovered to the extent that there was no evidence that they were significantly 
different from corresponding normative scores (p=0.644 for SF-12 PCS; p=0.924 for 
SF-12 MCS). This effect was maintained at T3 (3 months post-TAVI) (p=0.710 for 
SF-12 PCS; p=0.714 for SF-12 MCS). 
EQ-5D-VAS scored remained significantly below corresponding normative values at 
time point 2 (p<0.001) and time point 3 (p=0.026). 
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Changes in quartile scores followed similar patterns as mean scores; with 
improvement to normative values in SF-12 PCS and SF-12 MCS quartiles being 
generally achieved by the 2nd or 3rd time points. EQ-VAS quartile scores did not 
increase to normative values by time point 3. 
Table 5 shows scores on SF-12 and EQ5D VAS and the proportion of improvement 
at three time points respectively.  
Table 5 about here please 
These data show that at T3 over two thirds of the sample had improved in the SF12-
PCS, SF12 MCS and EQ-5D scores, compared with baseline scores. Repeated 
measures ANOVAs conducted on all three measures revealed evidence for 
significant changes in time in SF12-PCS (F1.58,45.8=5.76; p=0.010); in SF12-MCS 
(F2,48=5.98; p=0.004); and in EQ5D-VAS (F1.54,44.6=7.15; p=0.004). All such effects 
were moderate in magnitude (partial-2=0.166 for SF12-PCS; partial-2=0.171 for 
SF12-MCS; partial-2=0.198 for EQ5D-VAS).  
The magnitude of mean improvement in QoL was greater between T1 and T2 than 
between T2 and T3; and more patients showed an improvement of any magnitude 
between T1 and T2 than between T2 and T3. Bonferroni-adjusted pairwise 
comparison tests revealed SF-12 PCS scores at T1 to be significantly different from 
scores at T2 (p=0.018). SF-12 MCS scores at T1 were significantly different from 
scores at T3 (p=0.005). EQ5D-VAS scores at T1 were significantly different from 
scores at T3 (p=0.005). 
 
 
18 
 
Discussion  
TAVI is set to become a mainstream treatment in many high and middle-income 
countries  but decisions about who should receive this expensive treatment remain 
contentious. Whilst it is important to identify the clinical benefits of TAVI, it is equally 
important to understand the impact of TAVI on self-reported QoL. Most studies,8-9 
report improvements in the average QoL scores recorded after TAVI compared to 
baseline. However these data do not fully explain how and why changes take place.  
To our knowledge this is the first mixed-methods study that provides a detailed 
account of TAVI patients’ perspectives on the impact of TAVI on QoL during the first 
3 months of recovery. There is limited published literature for direct comparison,15 
making this study an important first step in understanding patients’ views about the 
impact of TAVI.  
Before TAVI consultation, participants had a limited awareness about the likelihood 
of AS shortening their life-span. A lack of understanding  amongst patients about 
their diagnosis, and/or prognosis, is not uncommon, as the heart failure trajectory is 
unpredictable, and conversations about life expectancy are challenging for all those 
involved.29  The pre-TAVI consultation may have been the first time that such 
information has been shared bringing 'mortality' to the forefront of discussions as. a 
potential risk associated with TAVI, although  such predictions can only be 
moderately accurate.30 The decision to have TAVI was influenced by the participants' 
perceived QoL. Those with a significant symptom burden felt that they had little 
choice. This finding is supported by others.14 Over a third of participants had SF-12 
MCS scores, greater than population norms, at baseline which may reflect an 
improvement in mental health due to TAVI treatment being imminent after several 
months on the waiting list.   
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Findings illustrate the considerable symptom burden endured by participants leading 
up to TAVI. Shortness of breath was experienced by many participants and is 
reported by other TAVI recipients.14  The symptom burden restricted functional and 
social activities leading to a negative impact upon QoL.  
Patients perceived TAVI as a treatment option that extended their life.. Many 
participants expressed their relief at surviving TAVI and viewed it as transforming 
their QoL. Questionnaire data showed that a large proportion of participants had 
improved QoL scores post TAVI compared to baseline.  
Regardless of the outcome, having the TAVI procedure changed participants' views 
about their life. Change was mediated through two mechanisms, although not all 
participants experienced both. Firstly, most participants experienced symptomatic 
relief, which provided tangible proof of an improvement in their heart health. 
Participants often reported increased energy levels and mobility leading to greater 
independence in daily living and leisure activities. Improvements in the QoL scores 
on the SF-12 and EQ5D VAS supported patients’ accounts. Those patients 
diagnosed with other co-morbidities did not tend to report a noticeable improvement. 
This is an important consideration in choosing those who may benefit most from 
TAVI. Comorbidities in people with AS are especially prevalent, with up to 84% and 
59% of patients with AS living with frailty or COPD respectively.33  Little is known 
about the impact of comorbidities on survival, QoL, readmission rates and 
functionality after TAVI. Geriatric syndromes such as frailty, falls, cognitive decline 
and delirium impact on QoL and recovery following TAVI.33   
Secondly participants reported feeling 'safe' as they perceived that they no longer 
faced imminent death. This increased their feelings of confidence and security. This 
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response is understandable as participants had survived both the waiting time, which 
is known to be anxiety- provoking,14,31 and a relatively risky medical procedure.9  
Data from the SF-12 and EQ5D-VAS showed statistically significant improvements 
across all QoL domains at 3 months compared to baseline, which reflects findings of 
other studies.11 The magnitude of improvement is likely to be clinically significant 
when examined in the context of other studies using the SF-12;34 however the study 
was not powered with this in mind, but rather to support the qualitative data set.  
As with all studies there are limitations that should be considered. The main one is 
that the sample was taken from a single regional centre but findings may be 
transferable across similar contexts. A major strength of the study is the triangulation 
of research methods which provide a robust account of the TAVI recovery 
experience with data from longitudinal in-depth interviews and validated outcome 
measures. Future research should focus upon how the physical and mental 
components of QoL interact. The development of a disease specific QoL measure 
for this population is recommended.    
There are several clinical implications arising from this study. Health professionals 
could use the TAVI consultation as a trigger for discussions about advanced care 
planning and to explore patients’ beliefs and preferences concerning quality and 
quantity of life. A simple survey administered in advance of the TAVI consultation 
could serve as a mechanism to facilitate such discussions. Patients should have the 
option of having family or friends present during the TAVI consultation which may be 
distressing and staff may need additional education about communication skills to 
support them to broach difficult conversations. The timing of baseline QoL 
measurement should be carefully considered as being taken off a TAVI waiting list 
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may have an effect upon baseline measurements. Patients' accounts  illustrate   how 
TAVI impacts on QoL and may be integrated into information resources to support 
the TAVI decision making process.     
Conclusion 
Findings provide an account of TAVI recipients view about the impact of treatment 
on their QoL. TAVI was of variable benefit, producing considerable improvements in 
either mental or physical health in many participants, while a smaller proportion 
continued to deteriorate. Improvements in either mental or physical health influenced 
the opportunity and motivation to engage and participate in activities of daily living. 
The presence of other comorbidities influenced the scope of improvement following 
TAVI.  
Implications for practice 
 The TAVI consultation, which includes the communication of 
prognostic/diagnostic information, may influence levels of self-reported QoL 
recorded afterwards.  
 Future research should examine how multimorbidity influences TAVI 
outcomes such as QoL, mortality, morbidity and readmission, to improve 
understanding of who might benefit most from TAVI.  
 Health professionals could use the TAVI consultation as a trigger for 
discussions about advanced care planning and patients’ beliefs and 
preferences concerning quality and quantity of life. A simple survey could be 
administered in advance of TAVI consultation to better understand patients’ 
views and preferences about quality and length of life.   
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 Discussions about diagnosis and prognosis are potentially distressing. 
Patients should have the option of having family or friends to accompany 
them during the TAVI consultation. Staff may need additional education to 
support them in such difficult conversations. 
 There is evidence that most patients undergoing the TAVI procedure report 
significant increases in QoL. Physical and mental improvement appear to 
occur at different rates.   
 
 
 
 
Table 1. Descriptive summary of sample characteristics  
 
Variable Mean (SD) 
Age (years) 81.7 (7.36) 
MMSE transformed score 47.7 (10.5) 
Variable Frequency (valid %) 
Gender 
   Male 
   Female 
 
21 (39.6%) 
32 (60.4%) 
Support level 
   Carer 
   No carer 
 
21 (39.6%) 
32 (60.4%) 
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New York Heart Association Classification 
    I 
    II 
   III 
   IV 
 
0 
10 (18.9%) 
36 (67.9%) 
7 (13.2%) 
 
 
 
Table 2:  Numbers of patients and type of data collected at each time point 
 
  
 
Data collection 
Time points 
T1. Pre-TAVI data 
collected  
  
T2. 1 month post-
TAVI data collected  
T3. 3 month post-
TAVI data collected  
SF-12 v2 
 
45 40 39 
EQ-5D 
 
45 41 40 
Qualitative 
interview 
n/a 46 43 
 
  
 
 
Pre-Publication Version Heart and Lung 
 
Table 3: Comparison of SF-12 component scores pre and post TAVI with Population  
 
Norms of adults aged 75 years+ (mean age of sample 81.7 years). PCS (Physical 
Component Scale) MCS (Mental Component Scale) 
 
 
  
 SF-12 
PCS 
(Norms 
75+) 
SF-12  
T1 
PCS 
SF-12  
T2 
PCS 
SF-12  
T3 
PCS 
SF-12 
MCS 
(Norms 
75+) 
SF-12 
T1  
MCS 
SF-12  
T2 
MCS 
SF-12  
T3 
MCS 
Mean 
 
38.68 32.06 38.04 39.28 50.06 43.09 50.22 50.70 
25th 
Percentile 
 
29.37 25.73 32.22 31.59 40.48 32.00 42.88 42.09 
50th 
Percentile 
 
38.68 31.70 38.04 38.55 53.53 41.52 51.36 49.97 
75th 
Percentile 
 
47.77 37.96 42.87 46.02 58.89 55.28 59.13 60.12 
Standard 
Deviation 
 
11.04 8.05 8.66 10.05 10.94 13.53 10.66 10.80 
Range 
 
17.0 – 
57.0 
18.8 - 
52.2 
18.9 -
56.7 
17.8 - 
56.7 
22.0 – 
69.0 
20.5 - 
69.6 
21.8 - 
64.5 
26.1-
66.5 
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Table 4: Comparison of EQ5D-VAS component scores pre and post TAVI with 
Population Norms of adults aged 70 years+ (mean age of sample 81.7 years) 
 EQ5D-VAS 
(Norms 70+) 
EQ5D-VAS 
T1  
EQ5D-VAS 
T2 
EQ5D-
VAS T3 
Mean 
 
79.0 57.2 66.3 73.3 
25th Percentile 
 
73.5 50.0 51.3 61.3 
50th Percentile 
 
80.0 50.0 62.5 75.0 
75th Percentile 
 
92.0 75.0 80.0 80.0 
Standard 
Deviation 
 
22.6 18.7 17.5 15.7 
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Table 5. Proportions of patients showing improvement on outcome measures 
between time points 
Measure Improvement: T1 – T2 Improvement: T2 – 
T3 
Improvement: T1 – T3 
EQ5D-VAS 20/37 (54.1%) 19/36 (52.8%) 24/34 (70.6%) 
SF12-PCS 26/37 (70.3%) 17/36 (47.2%) 24/34 (70.6%) 
SF12-MCS 25/37 (67.6%) 18/36 (50.0%) 27/34 (79.4%) 
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1. Shortened 
Life
3. Extended Life
2. Limited  Life 4. Changed  Life
Impact of TAVI on Quality of Life
1.1 Facing Mortality
The interview went something like this. My son said can my 
Dad have his operation next year, and they said no. Can he 
wait until after Christmas? ...and so he said, well what 
happens if I don’t have it? He’d be dead within a year. 
(Male subject 9, 88 yrs, NYHA III).
1.2 Deciding to have TAVI
‘The quality of life I had was so poor by that time it was well 
worth the risk’ (Female 27, 91 yrs NYHA IV)
2.1 Symptom burden
It was pretty drastic really. I couldn’t breathe. I could only 
walk a few yards , I couldn’t breathe at all’. (Female subject 
14, 87 yrs, NYHA III).
2.2 Functional and social restrictions
‘Some days I wished it was all over, I really did, because it 
was so painful to breathe and well, your life isn't the same, 
you can’t get out, can’t go shopping you see on my own, or 
anything’ (Female subject 26, 84 yrs, NYHA III).
3.1 Survival
‘I’m just thankful its over and done with and there is a 
light at the end of the tunnel where it wasn't before 
(Female 5, 86 yrs NYHA III)
‘I’ve got maybe a few more years to live’ (Male subject 
15, 87 yrs, NYHA III)
4.1 Symptomatic relief 
‘Well I knew I was feeling better because I aren’t 
breathless (Female subject 5, 86 yrs, NYHA III). 
‘Well I do exactly what I used to do ten years ago. You 
know I do my garden, go shopping, go to the gym’ 
(Male subject 21, 85 yrs, NYHA II).
4.2 Feeling Safe and secure
‘I want to feel as though I can do what I want, go 
where I want, not bother, not worry about anything, 
you know like chest pains or anything like that’ (Male 
25, 82 yrs NYHA III)
‘Well peace of mind, thinking, right I can, (Male subject 
36, 72 yrs, NYHA III)
Feeling safe
Altered symptom burden
  
 
 
 
 
 
 
Figure 1. Patients’ perceptions of the impact of TAVI on quality of life 
 
 
Pre-Publication Version Heart and Lung 
 
References 
1. World Health Organisation Global strategy and action plan on ageing and 
health (2016-2020) accessed on January 8th 2017 at 
http://www.who.int/ageing/global-strategy. 
 
2. Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: 
disease prevalence and number of candidates for Transcatheter aortic valve 
replacement: a meta-analysis and modelling study J Am Coll Cardiol, Volume 62, 
2013, pp.1002-12. 
 
3. World Health Organisation and National Institute on Aging, Health and 
Aging (2011) accessed on January 8th 2017 at nia.nih.gov. 
 
4. Bach DS, Siao D, Girard SE et al. Evaluation of patients with severe 
symptomatic aortic stenosis who do not undergo aortic valve replacement: the 
potential role of overestimated operative risk Circ Cardiovasc Qual Outcomes 
Volume 2, 2009, pp. 533-9. 
 
5. Andersen HR, Knudsen LL, Hasenkam JM. Transluminal implantation of artificial 
heart valves. Description of a new expandable aortic valve and initial results with 
implantation by catheter technique in closed chest pigs Eur Heart J, Volume 13, 
1992, pp. 704-708. 
 
6. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, 
Anselme F, Laborde F, Leon M. Percutaneous transcatheter implantation of an 
 
 
Pre-Publication Version Heart and Lung 
 
aortic valve prosthesis for calcific aortic stenosis: first human case description. 
Circulation, Volume 106, 2001, pp. 3006-8. 
 
7. Smith C R, Leon M B, Mack M J, Miller D C, Moses J W, Svensson L G. et al. 
Transcatheter versus surgical aortic-valve replacement in high-risk patients. N 
Engl J Med. 2011, Volume 364, 2011, pp. 2187–2198. 
 
8. Nielsen H H, Klaaborg K E, Nissen H, Terp K, Mortensen P E, Kjeldsen B J. et al. 
A prospective, randomised trial of transapical transcatheter aortic valve 
implantation vs. surgical aortic valve replacement in operable elderly patients with 
aortic stenosis: the STACCATO trial. EuroIntervention, Volume 8, 2012, pp. 383–
389. 
 
9. Biagioni C, Salinas P, Nombela-Franco L, Jimenez-Quevedo P Update on 
Transcatheter Aortic Valve Implantation EMJ Int Cardiol, Volume 4, Issue 1, 2016, 
pp. 91-99. 
 
10. Vahanian A, Alfieri O, Al-Attar N et al. Transcatheter valve implantation for 
patients with aortic stenosis: a position statement from the European Association 
of cardiothoracic Surgery (EACTS) and the European Society of Cardiology 
(ESC), in collaboration with the European Association of Percutaneous 
Cardiovascular Interventions (EAPCI) EuroIntervention Volume 4, 2008, pp. 193-199 
(p195). 
 
11. Kim CA, Rasania SP, Afilalo J, Popma JJ, Lipsitz LA, Kim DH Functional Status 
 
 
Pre-Publication Version Heart and Lung 
 
and Quality of Life After Transcatheter Aortic Valve Replacement: A Systematic 
Review Ann Intern Med. Volume 160, 2014, pp. 243-254. 
 
12. Sehatzadeh S, Doble B, Xie F, Blackhouse G, Campbell K, Kaulback K, Chandra 
K, Goeree R Transcatheter Aortic Valve Implantation (TAVI) for Treatment 
of Aortic Valve Stenosis: An Evidence Update Ont Health Technol Assess Ser, 
Volume 13, Issue 1, 2013, pp. 1–40.  
 
13. Kaier K, Gutmann A, Baumbach H, von Zur Muhlen C, Hehn P, Vach W, 
Beyersdorf F, Zehender M, Bode C, Reinokl J Quality of life among 
elderly patients undergoing transcatheter or surgical aortic valve replacement- a 
model-based longitudinal analysis. Health Qual Life Outcomes Volume 14, Issue 1, 
2016, pp. 109-18. 
 
14. Olsson K, Naslund U, Nilsson J, Hornsten A. Experiences of and Coping 
With Severe Aortic Stenosis Among Patients Waiting for Transcatheter Aortic 
Valve Implantation J Cardiovasc Nurs. Volume 31, Issue 3, 2016, pp. 255-61. 
 
15. Lytvyn L, Guyatt GH, Mania V, Siemieniuk RA, Zhang Y, Agoritsas T, Vandvik 
PO Patient values and preferences on transcatheter or surgical aortic 
valve replacement therapy for aortic stenosis: a systematic review. BMJ Open 
Volume 29, Issue 9, 2016, e014327. 
 
16. Hallan S, Asberg A, Indredavik B, Wideroe TE Quality of life after 
cerebrovascular stroke: a systematic review of patients’ preferences for different 
 
 
Pre-Publication Version Heart and Lung 
 
functional outcomes. J Intern Med Volume 246, 1999, pp. 309-16. 
 
17. Manara AR, Pittman JA, Braddon FE Reasons for withdrawing treatment in 
patients receiving intensive care. Anaesthesia Volume 53, 1998, pp. 523-8. 
 
18. Bakas T, McLennon SM, Carpenter JS, Buelow JM, Otte JL, Hanna KM, Ellett 
ML, Hadler KA, Welch JL (2012) Systematic review of health-related quality of life 
models. Health and Quality of Life Outcomes Volume 10, 2012, 134. 
 
19. World Health Organization: International Classification of Functioning, disability, 
and Health: Children and Youth Version: ICF-CY. Geneva: World Health 
Organization; 2007. 
 
20. Cresswell JW A Concise introduction to mixed methods research. Sage 
Publications New York, 2015. 
 
21. Reeves S, David Hodges B Qualitative research methodologies: 
ethnography BMJ Volume 337, 2008, a1020. 
 
22. Folstein MF, Folstein SE, McHugh PR Mini-mental State’. A practical method for 
grading the cognitive state of patients for the clinician J Psychiatr Res 
Volume 12, Issue 3, 1975, pp. 189-98. 
 
23. Astin F, Closs S J, McLenachan J, Hunter S, Priestley C Primary angioplasty for 
heart attack: mismatch between expectations and reality? Journal 
 
 
Pre-Publication Version Heart and Lung 
 
of Advanced Nursing, Volume 65, Issue 1, 2009, pp.72-83. 
 
24. Ritchie J and Spencer L. Qualitative data analysis for applied policy research in 
A.Bryman and RG Burgess (Eds) Analyzing qualitative data London: Routledge 
1993, pp173-194. 
25. Morrow SL. Quality and trustworthiness in qualitative research in counselling 
psychology Journal of Counseling Psychology Volume 52, Issue 2, 2005, pp. 250-
260. 
 
26. NVivo qualitative data analysis Software; QSR International Pty Ltd. Version 9, 
2011. 
 
27. Ware JE, Kosinski M, Keller SD A 12-item short-form health survey. Construction 
of scales and preliminary tests of reliability and validity. Med Care Volume 34, 1995, 
pp. 220-233. 
 
28. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol 
Group. Ann Med 2001;Volume 33, 2001, pp. 337-343. 
 
 
29. Selman L, Harding R, Beynon et al. Improving end-of-life care for patients 
with chronic heart failure: “Let’s hope it’ll get better, when I know in my heart of 
hearts it won’t” Heart Volume 93, 2007, pp. 963-967. 
 
30. Siontis GC, Tzoulaki I, Ioannidis JP Predicting death: an empirical 
 
 
Pre-Publication Version Heart and Lung 
 
evaluation of predictive tools for mortality. Arch Intern Med Volume 171, Issue 19, 
2011, pp. 1721-6. 
 
 
31. Lauck SB, Baumbusch J, Achtem L, Forman JM, Carroll SL, Cheung A, Ye J, 
Wod DA, Webb JG Factors influencing the decision of older adults to be assessed 
for transcatheter aortic valve implantation: an exploratory study. Eur J Cardiovasc 
Nurs Volume 15, Issue 7, 2016, pp. 486-494. 
 
32. Lindman BR, Patel JN Clinics in Geriatric Medicine Volume 32, Issue 2, 2016, 
pp. 306-314. 
 
33. Reynolds MR, Magnuson EA, Wang K, et al. Health-related quality of life 
after transcatheter or surgical aortic valve replacement in high-risk patients with 
severe aortic stenosis: Results from the PARTNER (Placement of AoRTic 
TraNscathetER Valve) Trial (Cohort A). J Am Coll Cardiol Volume 60, 2012, pp. 
548–558. 
 
 
